Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.
“[ImmTOR] induces tolerance in the presence of antigen, specific immune tolerance. Specifically, the issue we're trying to address in gene therapy is immunogenicity of AAV vectors to enable re-dosing. We have demonstrated this in a human proof-of-concept study last year and we are going into the first clinical indication in MMA in the second half of this year.”
Selecta Biosciences presented 3 posters at the 2022 American Society of Gene and Cell Therapy Annual Meeting, May 16-19, 2022, in Washington DCthat demonstrated the ability of their proprietary ImmTOR platform mitigate unwanted immune responses to adeno-associated virus capsids and potentially enable re-dosing of gene therapies.
Among these presenters was Takashi Kei Kishimoto, PhD, chief science officer, Selecta Biosciences, who presented the company’s findings on the immunogenicity and mitigation of immunogenicity mechanisms of the ImmTOR platform.
CGTLive spoke with Kishimoto and Carsten Brunn, PhD, president and chief executive officer, also of Selecta Biosciences, to learn more about the ImmTOR platform. They also discussed their first clinical gene therapy program in methylmalonic acidemia, SEL-302, initiating in the second half of 2022.